Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...

Scotiabank analyst George Farmer maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $133.00. The ...

Highlights:,Arcellx, Inc.,(NASDAQ:ACLX),experienced a 5.1% increase in its stock price.,UBS Group raised its price target for ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently ...

Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

Arcellx (ACLX) is up more than +3% after it gave data from a mid-stage trial of its experimental therapy for a form of blood cancer, which Baird said appears to support “best-in-class” efficacy for ...

have been observed to date in more than 150 patients dosed with anito-cel. Price Action: ACLX stock is up 6.46% at $90.01 during the premarket session at last check Monday.

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...